Promising Potential of Aficamten in Hypertrophic Cardiomyopathy Drives Buy Rating for Cytokinetics

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on CYTK stock, giving a Buy rating on June 4.

Tessa Romero’s rating is based on the promising potential of Cytokinetics’ aficamten, which is seen as a differentiated option in the treatment of hypertrophic cardiomyopathy (HCM). The key opinion leader (KOL) consulted highlighted aficamten’s advantages over existing treatments like Camzyos, particularly in terms of safety and efficacy. The KOL emphasized that aficamten’s pharmacological profile allows for higher dosing without compromising safety, potentially leading to better patient outcomes.
Moreover, the KOL expressed confidence in aficamten’s ability to treat patients who might not be suitable for Camzyos, such as those with lower ejection fractions and significant fibrosis. This positive outlook is further supported by the KOL’s intention to switch a majority of patients from Camzyos to aficamten upon its approval. The favorable view from a leading HCM expert at a high-volume institution reinforces the potential for aficamten to capture a significant market share, contributing to Tessa Romero’s Buy rating for Cytokinetics.

Romero covers the Healthcare sector, focusing on stocks such as Cytokinetics, ACADIA Pharmaceuticals, and EyePoint Pharmaceuticals. According to TipRanks, Romero has an average return of 9.2% and a 44.44% success rate on recommended stocks.

In another report released on June 4, Piper Sandler also maintained a Buy rating on the stock with a $107.00 price target.